Detalles de la búsqueda
1.
Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a "real-world" observational study in the United States.
Int J Clin Pract
; 70(9): 752-63, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-27550177
2.
Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States.
Value Health
; 15(5): 632-8, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22867771
3.
Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group.
Value Health
; 15(8): 1108-18, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23244814
4.
Quarterly assessment of short-acting beta(2)-adrenergic agonist use as a predictor of subsequent health care use for asthmatic patients in the United States.
J Asthma
; 47(6): 660-6, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20615167
5.
Geographical distribution of surgical capabilities and disparities in the use of high-volume providers: the case of coronary artery bypass graft.
Med Care
; 47(7): 794-802, 2009 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-19536028
6.
Incremental direct expenditure of treating asthma in the United States.
J Asthma
; 46(1): 73-80, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19191142
7.
Health disparities and social determinants of health among African-American women undergoing percutaneous coronary interventions (PCI).
J Cult Divers
; 15(3): 132-42, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-19025201
8.
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
PLoS One
; 13(11): e0205989, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30383768
9.
Discontinuation risk comparison among 'real-world' newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban.
PLoS One
; 13(4): e0195950, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29709012
10.
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
J Clin Oncol
; 36(8): 773-779, 2018 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29355075
11.
Depression, quality of life, and medical resource utilization in sickle cell disease.
Blood Adv
; 1(23): 1983-1992, 2017 Oct 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29296845
12.
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis.
Thromb Haemost
; 116(5): 975-986, 2016 Oct 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-27538358
13.
Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement.
Am J Hematol
; 85(1): 79-81, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20029954
14.
Patient time costs associated with sensor-augmented insulin pump therapy for type 1 diabetes: results from the STAR 3 randomized trial.
Med Decis Making
; 33(2): 215-24, 2013 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-23128579
15.
Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions.
Circ Cardiovasc Qual Outcomes
; 5(1): 113-9, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22147884
16.
Relationship between short-acting ß2-adrenergic agonist use and healthcare costs.
Am J Manag Care
; 17(1): 19-27, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21348565
17.
Race-differentiated outcomes in multiple special healthcare taxing districts.
Am J Prev Med
; 38(3): 311-6, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20171533
Resultados
1 -
17
de 17
1
Próxima >
>>